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M48U1 and Tenofovir combination 
synergistically inhibits HIV 
infection in activated PBMCs and 
human cervicovaginal histocultures
Giuseppina Musumeci1, Isabella Bon1, David Lembo2, Valeria Cagno2, Maria Carla Re1, 
Caterina Signoretto3, Erica Diani3, Lucia Lopalco4, Claudia Pastori4, Loïc Martin5, 
Gilles Ponchel6, Davide Gibellini3 & Kawthar Bouchemal6
Microbicides are considered a promising strategy for preventing human immunodeficiency virus 
(HIV-1) transmission and disease. In this report, we first analyzed the antiviral activity of the miniCD4 
M48U1 peptide formulated in hydroxyethylcellulose (HEC) hydrogel in activated peripheral blood 
mononuclear cells (PBMCs) infected with R5- and X4–tropic HIV-1 strains. The results demonstrate 
that M48U1 prevented infection by several HIV-1 strains including laboratory strains, and HIV-1 
subtype B and C strains isolated from the activated PBMCs of patients. M48U1 also inhibited infection 
by two HIV-1 transmitted/founder infectious molecular clones (pREJO.c/2864 and pTHRO.c/2626). In 
addition, M48U1 was administered in association with tenofovir, and these two antiretroviral drugs 
synergistically inhibited HIV-1 infection. In the next series of experiments, we tested M48U1 alone 
or in combination with tenofovir in HEC hydrogel with an organ-like structure mimicking human 
cervicovaginal tissue. We demonstrated a strong antiviral effect in absence of significant tissue toxicity. 
Together, these results indicate that co-treatment with M48U1 plus tenofovir is an effective antiviral 
strategy that may be used as a new topical microbicide to prevent HIV-1 transmission.
According to World Health Organization (WHO)1 approximately 37 million people worldwide are currently 
infected with HIV-1, with 2 million new cases of infection and 1.2 million deaths from AIDS-related causes 
per year. Almost 50% of infections worldwide are in women, and the majority of detectable infections occur in 
sub-Saharan Africa1,2, where 56% of the regional cases are in women. In addition, AIDS is the leading cause of 
death in women of reproductive age in this region1,3. These data indicate the need to develop useful approaches 
to protect women from HIV-1 infection, especially since sexual intercourse is the principal route of HIV-1 trans-
mission1. Indeed, some reports have indicated that approximately 85% of HIV-1 infections are transmitted by 
sexual intercourse4,5, and heterosexual contact is heavily involved in the spread of HIV-1. The use of combined 
antiretroviral therapy (cART) cannot eradicate HIV-1 infection in an individual, however cART counteracts the 
development of disease and dramatically increases the life expectancy6,7. Furthermore, the suppression of HIV-1 
replication by cART leads to a decrease in the viral load in a treated HIV-1 positive patient, which reduces the risk 
of HIV-1 transmission8. Unfortunately, all vaccine strategies that have been evaluated to date have failed to induce 
effective immunological protection from HIV-1 because of its genetic variability and cellular latency of HIV-19.
Behavioural approaches (i.e., male circumcision, condom use) have been used for preventing HIV-1 trans-
mission, but these methods are inefficient at reducing sexual transmission of HIV-1, particularly in sub-Saharan 
Africa, where one of the highest risk factors for acquiring HIV-1 in women is low condom use by the male 
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partner2,10. A promising strategy for inhibiting HIV-1 transmission is represented in microbicides11,12. Some 
mathematical models have demonstrated that the proper use of microbicides may decrease the number of infected 
women by interfering with the spread of HIV-1 infection13,14. In HIV-1 treatment, microbicides are drugs with 
antiretroviral properties, which are applied topically in the form of a vehicle gel or film to either the vaginal or 
rectal mucosa pericoitally11,12. The recent preparation of microbicides with long-term release from a vaginal ring 
could represent a valid form of pre-exposure prophylaxis15. It has been recently proposed that the use of specific 
drugs taken per os inhibits HIV-1 transmission increasing treatment compliance16–18. Early approaches to micro-
bicide application were developed using polyanionic gels and surfactant-based products applied in vaginal and 
rectal cell models, but were not reliable in preventing HIV-1 infection19. Furthermore, some trials using HIV-1 
attachment inhibitors, including PRO 2000, cellulose sulfate and Carraguard, failed to show anti-HIV-1 activity 
when these molecules were used as microbicides20–23. The first encouraging data on the use of microbicides to 
prevent transmission were obtained in the CAPRISA 004 study, during which a gel with tenofovir was applied to 
the vaginal mucosa and reduced the risk of acquiring HIV-1. The patients treated with tenofovir gel were 39% less 
likely to become infected with HIV-1 compared to the control group24. Similarly, pre-exposure chemoprophylaxis 
using oral administration of Truvada, a pharmacological preparation containing tenofovir, disoproxil fumarate 
and emtricitabine, resulted in a 44% reduction in the incidence of rectal transmission of HIV-1 among men who 
have sex with men25. Unfortunately, other studies carried out in cohorts of women treated with tenofovir gel treat-
ment (the VOICE and the FACTS 001 trials) or oral Truvada (the FEM PrEp study) did not confirm these initial 
results, due to low patient adherence to the treatment21,26.
Several new antiretroviral microbicides have been developed and shown to interfere with specific phases of the 
HIV-1 replication cycle. In particular, the most promising targets are those that inhibit HIV-1 entry and reverse 
transcription. HIV-1 entry inhibitors are considered valuable tools as microbicides, and specifically promising 
agents are those directed against the interaction of cellular CD4 and the HIV-1 gp120 protein since protection 
would be independent of co-receptor tropism. Previous studies with BMS-378806, dendrimers, CADA and min-
iCD4 mimetic peptides demonstrated their strong inhibitory effects on HIV-1 infection of histocultures in vitro 
and/or during studies using vaginal challenge of non-human primates with the SHIV-1162P3 strain, suggesting 
the potential use of these molecules as microbicides27–31. Recently, treatment regimens composed of two or more 
drugs that target different phases of the HIV-1 replication cycle have been considered to increase the overall anti-
viral effects of microbicides during HIV-1 transmission32,33. MiniCD4 M48U1 is a peptide that inhibits HIV-1 
infection34 through the binding with gp120, with a higher affinity (100-fold titer binding) than that of gp120 
binding soluble CD4, due to a higher rate of association and slow rate of dissociation34,35. This drug may be a good 
candidate as a microbicide because previous observations in a simian model demonstrated that M48U1 formu-
lated in hydroxyethylcellulose (HEC) and pluronic-based hydrogels inhibit HIV-1 infection36.
In this report, we studied the antiretroviral efficacy of miniCD4 M48U1 alone or in combination with tenofo-
vir in vitro in both PBMCs and cervicovaginal histocultures. We propose that this combination may be used as a 
novel microbicide for inhibiting HIV-1 transmission through sexual intercourse.
Methods
Virus stocks and drugs. HIV-1 X 4 or R5 strains were used for the experiments. HIV-1IIIb (subtype B, X4 
tropism), HIV-1ADA (subtype B, R5 tropism), HIV-1ARV-2 (subtype B, R5/X4 tropism), HIV-1RU132 (subtype G, 
R5 tropism), HIV-1BaL (subtype B, R5 tropism), and HIV-1CBL4 (subtype D, X4 tropism) were obtained from 
NIBSC (NIBSC, London, UK). Three HIV-1 subtype B isolates (HIV-1AMBR5N, HIV-1ARR5X4, and HIV-1CSBX4) 
were obtained from naïve (HIV-1AMBR5N R5 tropism) and cART-treated (HIV-1ARR5X4 R5/X4 tropism, HIV-1CSBX4 
X4 tropism) HIV-1-positive subjects. Two HIV-1 subtype C isolates (HIV-1FBR5N and HIV-1SLR5N, both R5 tro-
pism) were obtained from acutely infected naïve patients. For all the HIV-1 isolates, cellular receptor tropism was 
determined by classical genotyping method37. Stocks of reference HIV-1 strains were prepared in C8166 cells 
(HIV-1IIIb) or in activated PBMCs (HIV-1ADA, HIV-1ARV-2, HIV-1RU132, HIV-1BaL and HIV-1CBL4)38. The primary 
viral isolates were obtained from HIV-1-infected subjects using a co-culture technique, as described previously38. 
PBMCs from HIV-1 infected patients were obtained after giving their written consent for study, according to the 
Helsinki declaration. Briefly, the HIV-1IIIb stock was obtained by clarifying the supernatant of an HIV-1-infected 
C8166 culture free of bacteria contamination using low-speed centrifugation. The reference HIV-1 strains and 
primary isolates were obtained by culturing approximately 1 × 106 PBMCs obtained from the buffy coat of donor 
HIV-1 seronegative blood. The cultured PBMCs were treated for 72 h with phytohaemagglutin (PHA; 5 μg/ml, 
Sigma, St.Louis, MO, USA) plus IL-2 (10U/ml; Pierce, Rockford, IL, USA). The cell culture supernatants, after 
centrifugation at 7,000 rpm for 15 min, were tested twice per week for the presence of HIV-1 p24 core protein. The 
viral stocks were titrated with an HIV-1 gag p24 antigen ELISA kit (Biomerieux, Marcy L’Etoile, France). Viral 
stocks were assessed at a concentration of 1000 ng p24/ml and used in the experiments at final concentration of 
5 ng p24/ml.
The genomic sequence of each full-length transmitted/founder (T/F) HIV-1 strain was deduced using a math-
ematical model of HIV-1 sequence evolution during acute clinical infection and an experimental strategy based 
on single genome amplification (SGA) of plasma vRNA/cDNA, followed by direct sequencing of SGAs prod-
ucts without a cloning step39,40. The bona fide T/F infectious molecular clones (IMCs) including pTHRO.c/2626 
and pREJO.c/2864, were described previously by Ochsenbauer and coworkers41, and John C. Kappes and C. 
Ochsenbauer contributed the T/F IMCs to the NIH ARRRP for public availability. The 293T cell-derived stocks 
of replication competent IMCs were generated by transfection of proviral DNA using FuGENE 6, according to the 
manufacturer’s protocol (Promega, Madison, WI, USA). Supernatants containing virus were harvested 72 hours 
post-transfection, clarified at 1,800 rpm for 20 min, and frozen at −70 °C. Four replicates of five-fold diluted 
supernatants containing of T/F IMCs were added to a 96-well flat-bottom plate containing 1 × 104 TZM-bl cells 
per well in 10% D-MEM growth medium with 7.5 μg/mL of DEAE-dextran (Sigma) in a final volume of 200 μL. 
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After 72 hours of incubation at 37 °C, 100 μL of culture medium were replaced with 100 μL of Bright-Glo lucif-
erase reagent (Promega). After 2 minutes of incubation, 150 μL of the cell lysate were transferred to a 96-well 
white solid plate and luminescence was measured using a Victor Light 2030 luminometer (Perkin Elmer). Fifty 
per cent infectious dose (ID50) titres were defined as the reciprocal of the virus dilution yielding 50% positive 
wells (Reed-Muench calculation). 293T cells, TZM-bl cells and T/F IMCs were obtained through the NIH AIDS 
Research and Reference Reagent Program.
The M48U1 peptide42 was synthesized by Pepscan Presto Inc. (Lelystad, The Netherlands) using a solid phase 
peptide synthesis procedure. The M48U1 peptide contains a p-(cyclohexylmethyloxy)phenylalanine residue at 
aminoacid 23 able to enhance its affinity to the Phe43 cavity of gp12034,35, and was purified after refolding by 
reverse-phase high-performance liquid chromatography as described previously42. The sequence of M48U1 was 
previously published35. Tenofovir was obtained from NIBSC. HEC hydrogel was prepared as described in a pre-
vious report43. Briefly, the HEC hydrogel stock (1.5%) was prepared by adding 1.5 g of gelling polymer HEC 
(Natrosol 250 M Pharm, Aqualon, USA) to a vial containing citrate buffer (5 mM, pH 4.5). The final formulation 
was mixed with a mechanical stirrer until complete dissolution of the HEC powder. The M48U1 and/or tenofovir 
preparations were formulated by adding M48U1 and/or tenofovir to HEC hydrogel. Drug-containing hydrogels 
were then homogenized by magnetic mixing. The desired concentrations of drugs and HEC were obtained by 
performing appropriate dilutions of these molecules in RPMI 1640 medium (Gibco, Gaithersburg, MD, USA) 
immediately before their use in the experiments.
Cell isolation and activation. Peripheral blood samples were collected from healthy blood donors during 
routine laboratory analyses at the Blood Bank of S. Orsola-Malpighi Hospital in Bologna according to the rules 
established by Italian law (Legislative Decree 03-03-2005, published in G.U. n. 85, 13.04.2005). No approval from 
the Ethics Committee was requested because all blood samples were obtained from anonymous donors with no 
identifying information. A Ficoll gradient (Ficoll-Histopaque, Pharmacia, Uppsala, Sweden) was used to sep-
arate the PBMCs from the blood. PBMCs were seeded in RPMI 1640 plus 10% FCS and 2 mM L-glutamine at 
5 × 105 cells/ml. The PBMCs were activated by treatment with PHA (5 μg/ml; Sigma) plus IL-2 (10 U/ml; Pierce) 
treatment for three days. The culture medium was replaced every three days with fresh medium (RPMI 1640 plus 
10% FCS, 2 mM L-glutamine and 10 U/mL IL-2).
HIV-1 infection and antiviral treatment. The HIV-1BaL and HIV-1IIIb laboratory strains (5 ng/ml of 
HIV-1 gag p24) were pre-incubated for one hour at 37 °C with increasing concentrations of either M48U1 (0, 
0.0033, 0.033, 0.33, 1 or 3.3 μM) formulated in 0.25% HEC or tenofovir (0, 0.5, 1.25, 2.5, 5 or 10 μM) formu-
lated in 0.25% HEC. Then, the solutions were added to activated PBMCs that were adjusted to a final density 
of 1 × 106 cells/ml for a two hour incubation at 37 °C. After four washes in PBS, the cells were seeded at 5 × 105 
PBMCs/ml in culture plates containing fresh medium with various concentrations of the M48U1 or tenofovir 
formulations. The HIV-1 gag p24 content was determined at seven days post-infection in the culture supernatant 
using the HIV-1 p24 antigen ELISA kit (Biomerieux). Mock-infected PBMCs were used as the negative con-
trol. The experiments using other laboratory strains and viral isolates were performed as indicated above with a 
single concentration of M48U1 (1 μM) or tenofovir (5 μM) formulated in 0.25% HEC. The viability of the acti-
vated PBMCs was evaluated by the Trypan Blue exclusion technique in the presence of various concentrations of 
M48U1 or tenofovir formulated in 0.25% HEC using the protocol described above.
To analyze the inhibition of infection with HIV-1 T/F strains, a final concentration of 1 μM or 6.7 μM of 
M48U1 and 5 μM or 20 μM of tenofovir both in 0.25% HEC, were plated in triplicate in a 96-well flat bottom plate 
in 10% D-MEM containing 20 TCID50 of each T/F IMC (150 μL/well), and incubated for 1 hour at 37 °C. TZM-bl 
cells (1 × 104/well in a 100 μL volume) in 10% D-MEM growth medium containing DEAE-dextran (Sigma) at a 
final concentration of 7.5 μg/mL were then added to the plate. Assay controls included replicate wells of TZM-bl 
cells alone in HEC 0.25% (cell control) and TZM-bl cells with virus (virus control). Following 72 hours of incu-
bation at 37 °C, 150 μL of culture medium were removed from each well and replaced with 100 μL of Bright-Glo 
luciferase reagent (Promega). After 2-minutes of incubation, 150 μL of the cell lysate were transferred to a 96-well 
white solid plate and luminescence was measured using a Victor Light 2030 luminometer (Perkin Elmer). The 
percentage of infection for each T/F strain was calculated by comparing the relative luminescence units (RLU) of 
the virus control wells after subtraction of the cell control RLU44.
Drug combination analysis. Different concentrations of tenofovir (0, 0.1, 0.5, 1.25, 2.5, 5 or 10 μM) and 
M48U1 (0, 0.001, 0.005, 0.03, 0.15, 0.75 or 1.5 μM) were co-formulated in 0.25% HEC and tested in activated 
PBMCs challenged with HIV-1BaL (5 ng/ml of HIV-1 gag p24) using the protocol described above. The HIV-1 
gag p24 content was determined at seven days post-infection in the culture supernatants using the HIV-1 p24 
antigen ELISA kit (Biomerieux). The data were analyzed using an isobologram according to previously reported 
methods45–47. In brief, IC50 values were used to calculate the fractional inhibitory concentration (FIC) as follows: 
FICx (EC50 of compound “X” in combination/IC50 of compound alone); FICy (IC50 of compound “Y” in com-
bination/IC50 of compound alone). When the FIC index, which corresponds to the sum of the FIC values of the 
combined compounds (FIC index = FICx + FICy), is equal to 1, the combination is additive; when the FIC index 
is between 1.0 and 0.5, the combination is partially synergistic; when it is < 0.5, the combination is synergistic; 
when it is between 1.0 and 2.0, the combination is partially antagonistic; and finally, when it is > 2.0, the combi-
nation is antagonistic. The combinations of drug concentrations M48U1/tenofovir were: 0/10 μM; 0.001/5 μM; 
0.005/2.5 μM; 0.03/1.25 μM; 0.15/0.5 μM; 0.75/0.1 μM and 1.5 /0 μm. Data from drug combination studies were 
also evaluated using the MacSynergy II analysis program for multiple drug interactions48.
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Analysis of the effects of M48U1 and/or tenofovir formulated in 0.25% HEC in the HIV-1-infected 
cervicovaginal histoculture model. The EpiVaginal Tissue Model (VLC-100FT; MatTek Corporation, 
Ashland, MA, USA) was maintained in a 24-well plate according to the manufacturer’s instructions. This in 
vitro-reconstituted, full thickness vaginal tissue model was formed using a complete, stratified vaginal–ectocer-
vical epithelial layer with Langerhans cells and an additional lamina propria containing fibroblasts. On the apical 
surface of each tissue-containing well, we added 6.7 or 0.67 μM M48U1 in 0.25% HEC and 2 or 20 μM tenofovir in 
0.25% HEC. We used two different mixtures co-formulated in 0.25% HEC: i) 0.67 μM M48U1 plus 2 μM tenofovir 
and ii) 6.7 μM M48U1 plus 20 μM tenofovir. Subsequently, the wells were challenged with HIV-1BaL (25 ng p24/tis-
sue well) for 24 hours. Mock-infected 0.25% HEC-treated wells were used as negative control. The apical surface 
of each tissue was washed twice with PBS after incubation with HIV-1BaL and the same formulations were added 
on day 1 for 24 hours. The underlying media was changed every day, and cervicovaginal tissues were harvested 
on day 4 post-infection.
Total DNA was extracted and purified from the tissues using the QIAamp DNA Mini Kit (Qiagen, Hilden, 
Germany). Proviral DNA was quantified by real-time quantitative PCR assay using the HIV-1 DNA qPCR kit 
(Diatheva, Fano, Italy) based on SYBR Green chemistry as indicated by the manufacturer. Briefly, the amplification 
was carried out in 20 μL reactions consisting of 10 μL of HIV-1 DNA 2X master mix (Diatheva), which contained 
0.5 μL of Hot-Rescue PLUS DNA polymerase (Diatheva) plus long terminal repeat (LTR) region-specific oligos 
(forward primer: 5′-TAGCAGTGGCGCCCGA-3′ and reverse primer 5′-TCTCTCTCCTTCTAGCCTCCGC-3′ 
designed to amplify a 161 bp fragment49 derived from the 5′-LTR U5 end to the Gag-Pol start site of the sequence 
of HIV-1) and 200 ng of DNA. Total DNA amount was determined by spectrophotometry. The amplification was 
carried out as follows: an initial cycle of denaturation step at 95 °C for 15 minutes, followed by 10 cycles of dena-
turation at 95 °C for 15 seconds and annealing/extension at 68 °C for 35 seconds, and a final 35 cycles of denatura-
tion at 95 °C for 15 seconds and annealing/extension with fluorescence acquisition at 68 °C for 35 seconds. At the 
end of the amplification cycles, a quantitative analysis was performed by interpolation of the data obtained using 
a standard curve. The data were normalized to those of a parallel amplification of the β-globin gene as described 
previously31. The manufacturer specified that the limit of detection of the assay was three viral copies/500 ng total 
DNA.
Analysis of the irritation potential of M48U1 and tenofovir in the EpiVaginal system. The cyto-
toxicity of M48U1, tenofovir and both in combination formulated in 0.25% HEC hydrogel was analysed with an 
MTT ET-50 tissue viability assay, followed by determining the level of lactate dehydrogenase (LDH). We tested 
the irritation potential of 6.7 μM M48U1 alone, 20 μM tenofovir alone and 6.7 μM M48U1 plus 20 μM tenofovir 
formulated in 0.25% HEC hydrogel following administration to the apical surface of cervicovaginal cultures and 
incubation for 1, 4, 18 or 96 hours. At the end of the incubation at 37 °C, the hydrogel was discarded and the cervi-
covaginal cultures were washed with PBS to remove any residual hydrogel. The cervicovaginal cultures were ana-
lyzed using the MTT kit protocol (MatTek Corporation). Cell cultures incubated with sterile distilled water were 
employed as a negative control. Triton X-100 (1%)-treated cultures were used as the positive control. The LDH 
cytotoxicity detection kit (TaKaRa Bio Inc, Japan) was used to detect LDH release from the tissues according to 
the manufacturer’s protocols. The inflammatory response was evaluated by measuring the level of cytokine IL-1α 
released into the culture medium of EpiVaginal tissues treated with tenofovir and M48U1 for 1, 4, 18 or 96 hours, 
as previously reported50. After incubation, the concentration of IL-1α in the culture medium was measured using 
the IL-1α ELISA Kit, according to the manufacturer’s instructions (Bender Medsystem, Wien, Austria). The con-
centration of IL-1α was calculated by interpolation from a standard calibration curve.
Statistical analyses. The results were expressed as the mean ± standard deviations (SD) of three sepa-
rate experiments performed in duplicate or triplicate. Non-parametric Mann Whitney, one-way ANOVA and 
two-way ANOVA followed by Bonferroni test were used for the statistical comparisons. The IC50 and 95% CI 
values were calculated using the Prism (GraphPad Software, San Diego, CA) and ic50tk (www.ic50.tk) software.
Results
Infection of activated PBMCs with R5-tropic HIV-1BaL or X4-tropic HIV-1IIIb was inhibited by 
treatment with HEC formulations of miniCD4 M48U1 or tenofovir. The antiviral activity of each 
drug, M48U1 and tenofovir, formulated in 0.25% HEC hydrogel was determined in an activated PBMC model. In 
the first set of experiments, we pre-incubated either R5-tropic HIV-1BaL or X4-tropic HIV-1IIIb (5 ng/ml of HIV-1 
gag p24) with increasing concentrations of M48U1 formulated in 0.25% HEC for one hour at 37 °C in RPMI 1640 
medium. This mixture was added to PBMCs activated with IL-2 and PHA for a two-hour incubation at 37 °C. To 
evaluate the antiviral effect of M48U1, the level of HIV-1 gag p24 protein in the culture supernatant was deter-
mined at seven days post-infection using an ELISA. A significant decrease (p < 0.05; Mann Whitney test) in the 
HIV-1 p24 level was found (Fig. 1). The IC50 of M48U1 was calculated to be 43.4 nM (95% CI 17.8–106.72) and 
33.2 nM (95% CI 22.65–48.64) in cultures infected with HIV-1BaL (Fig. 1A) and HIV-1IIIb (Fig. 1B), respectively.
Although the antiretroviral activity of tenofovir has been well-characterized28,33,51,52, we evaluated the effects 
of tenofovir formulated in 0.25% HEC specifically on HIV-1 replication under the same experimental conditions 
as above. We used increasing concentrations of tenofovir formulated in 0.25% HEC to treat activated PBMCs 
challenged with HIV-1BaL or HIV-1IIIb. For both strains assessed, the level of HIV-1 p24 in the cell culture super-
natant on day 7 post-infection showed a concentration-dependent inhibition of infection by tenofovir. The IC50 
of tenofovir was found to be 1.22 μM (95% CI 1.1–1.4) and 1.08 μM (95% CI 0.68–1.7) for HIV-1BaL (Fig. 1C) and 
HIV-1IIIb (Fig. 1D), respectively.
To rule out the possibility that the antiviral effects were related to the formulation of the drugs in 0.25% HEC, 
we analyzed whether M48U1 in 0.25% HEC or tenofovir in 0.25% HEC may induce adverse effects on activated 
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PBMCs. Increasing concentrations of M48U1 or tenofovir in 0.25% HEC were added to cell cultures, and the 
viability was determined by the Trypan Blue exclusion assay. The viability of the activated PBMCs was not affected 
by either of the drugs formulated in 0.25% HEC compared to untreated PBMC cell cultures, showing a CC50 
value > 10 μM for M48U1 and a CC50 value > 20 μM for tenofovir (Supplementary Figure 1).
Individual infections with HIV-1 reference strains, viral isolates from patients and transmitted/
founder infectious molecular clones were effectively inhibited by treatment with M48U1 or 
tenofovir in 0.25% HEC. Because different HIV-1 strains may have different IC50 values for M48U1 and 
tenofovir, we chose a concentration of each drug that inhibited over 90% of HIV-1BaL and HIV-1IIIb replication. 
In the next series of experiments, we tested the antiretroviral activity of 1 μM M48U1 in 0.25% HEC or 5 μM 
tenofovir in 0.25% HEC in PBMCs challenged with different HIV-1 reference and patient strains. In addition 
to R5-tropic HIV-1BaL and X4-tropic HIV-1IIIb, four classical laboratory strains, including R5-tropic HIV-1ADA 
and HIV-1RU132, R5/X4 dual-tropic HIV-1ARV-2 and X4-tropic HIV-1CBL4, were used to infect activated PBMCs. 
By analyzing the level of p24 protein in the cell supernatant (Fig. 2A,B) we found that each drug suppressed the 
replication of all HIV-1 strains tested (p < 0.05).
We also isolated and characterized HIV-1 subtype B and C strains from five patients: three naïve patients 
and two patients with therapeutic failure and resistance to certain protease and reverse transcriptase inhibitors. 
Sequence analysis demonstrated that the naïve patients were infected with R5-tropic HIV-1 subtype B (HIV-
1AMBR5N) and subtype C strains (HIV-1FBR5N and HIV-1SLR5N), whereas the two patients with cART failure were 
infected with R5/X4-tropic HIV-1ARR5X4 or X4-tropic HIV-1CSBX4 B subtype strains. Treatment with 1 μM M48U1 
in 0.25% HEC (Fig. 2A) prevented infection of PBMCs with all HIV-1 subtype B and C isolates (p < 0.05; Mann 
Whitney test). On the other hand, 5 μM tenofovir in 0.25% HEC (Fig. 2B) was tested only with the HIV-1 subtype 
B and C strains that were isolated from three naïve patients, in the absence of mutations (inducing resistance 
to NRTI). Tenofovir in 0.25% HEC inhibited viral replication in all three cases (p < 0.05; Mann Whitney test), 
demonstrating that this formulation prevented HIV-1 infection of activated PBMCs with both laboratory and 
patient-derived strains.
Because the use of transmitted/founder infectious molecular clones (T/F IMCs), would be both informative 
for understanding HIV-1 transmission and provide new opportunities to find drugs that block the earliest stages 
Figure 1. M48U1 and tenofovir formulated in 0.25% HEC each inhibited the replication of both R5-tropic 
HIV-1BaL and X4-tropic HIV-1IIIb in activated PBMCs. Either the R5-tropic HIV-1BaL or X4-tropic HIV-1IIIb 
(5 ng/ml of HIV-1 gag p24) strain was incubated for 1 hour at 37 °C in RPMI 1640 medium with increasing 
concentrations of M48U1 (A,B) or tenofovir (C,D) formulated in HEC at a final concentration of 0.25%. After 
this incubation, these solutions were used to resuspend activated PBMCs for 2 hours at 37 °C. HIV-1 replication 
was monitored by a HIV-1 p24 ELISA assay on the cell culture supernatants performed on day 7 post-infection. 
The data were expressed as the means ± standard deviations (±SD) of the level of HIV-1 gag p24 relative to 
untreated controls (set to 100%). Three experiments in triplicate were performed.
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of HIV-1 transmission, we also analysed the antiretroviral activity of 1 or 6.7 μM M48U1 in 0.25% HEC and 5 
or 20 μM tenofovir in 0.25% HEC in TZM-bl cells challenged separately with two T/F IMCs, pREJO.c/2864 and 
pTHRO.c/2626. As shown in Fig. 2C,D, a clear decrease in viral infectivity was observed when experiments were 
performed in the presence of M48U1 or tenofovir). A dose-dependent response activity was found for tenofovir 
(Fig. 2D) but not for M48U1 (Fig. 2C), which showed the maximum level of inhibition at both concentrations 
of 1 and 6.7 μM. In fact, treatment with 1 or 6.7 μM of M48U1 in 0.25% HEC induced a reduction a 96.7% 
(±0.07) and 96.6% (±0.05) reduction in viral replication, respectively for pREJO.c/2864 or 95% (±0.09 or ±0.15) 
for pTHRO.c/2626. A reduction in viral replication of pREJO.c/2864 of 86.8% (±3.08) and 95% (±1.28) was 
observed in the presence of 5 or 20 μM tenofovir in 0.25% HEC respectively. The same concentration of tenofovir 
decreased viral replication of pTHRO.c/2626 by 78% (±0.51) and 93% (±2.04), which supports our data obtained 
with strains belonging to HIV-1 subtypes B and C.
Synergistic effects of M48U1 and tenofovir formulated in 0.25% HEC on HIV-1 replication. 
Previous studies demonstrated that tenofovir acts synergistically with several antiretroviral drugs, including some 
NRTIs, PI and entry inhibitors28,33. We therefore explored whether treatment with M48U1 and tenofovir com-
bined in 0.25% HEC has a synergistic effect on viral replication in an in vitro cellular model of activated PBMCs 
infected with the R5-tropic HIV-1BaL strain. To do so, the combined activity of tenofovir and M48U1 in serial 
concentrations was evaluated by examining the amount of HIV-1 p24 present in the cell supernatant on day 7 and 
synergy was determined with the isobologram. Figure 3A shows the isobologram, where the FIC values achieved 
for several combinations of concentrations of the two antiretroviral drugs demonstrated their synergistic activity. 
The FIC index was <0.5, clearly indicating the presence of synergistic effects between the drugs. A parallel anal-
ysis with the MacSynergy II48 program demonstrated synergism between M48U1 and tenofovir, reaching a peak 
of 14.52 μM2 synergy volume with a total 68.44 μM2% of synergy volume thus confirming the synergism between 
Figure 2. M48U1 in 0.25% HEC and tenofovir in 0.25% HEC each inhibited several laboratory strains 
and patient-derived HIV-1 isolates. Treatment with either 1 μM M48U1/0.25% (A) or 5 μM tenofovir/0.25% 
HEC (B) inhibited the replication of all tested laboratory and patient-derived strains. The HIV-1 strain tropism 
was determined with a sequencing analysis for the patient-derived strains. The combination of the two HIV-1 
drugs inhibited HIV-1 replication independent of the HIV-1 strain tropism. HIV-1 replication was monitored 
by the HIV-1 p24 ELISA assay using cell culture supernatants obtained on day 7 post-infection. The data were 
expressed as the means ± standard deviations (±SD) of the level of HIV-1 gag p24 relative to untreated controls 
(set to 100%) for every HIV-1 strain. Three experiments in triplicate were performed. Analysis of antiretroviral 
activity of 1 μM M48U1 in 0.25% HEC (C) or 5 μM tenofovir in 0.25% HEC (D) performed in TZM-bl cells 
infected with pREJO.c/2864 and pTHRO.c/2626 T/F IMCs. The percentage of infection of each T/F was 
calculated comparing the relative luminescence units (RLUs) of the virus control wells, after subtraction of 
cell control RLUs and the data were expressed as the means ± standard deviations (±SD). Each sample was 
performed in triplicate and was repeated in three independent experiments.
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the two drugs (Fig. 3B). The Trypan Blue exclusion assay was employed to determine whether these co-treatments 
could exert cytotoxic effects that would explain the antiretroviral effects of the drugs. None of combinations 
with the higher concentrations of these antiretroviral compounds exhibited significant effects on the viability of 
activated PBMCs (p > 0.05; one-way ANOVA test; Fig. 4), indicating that the synergistic antiviral effect was not 
associated with cytotoxicity but was likely related to the inhibitory effects of M48U1 and tenofovir on two distinct 
phases of the HIV-1 replication cycle.
M48U1 and tenofovir inhibited the HIV-1 replication in cervicovaginal histocultures. In the 
previous experiments, we demonstrated that tenofovir and M48U1 exerted synergistic antiretroviral effects 
when formulated in HEC using an activated PBMC model. We next investigated the antiretroviral effects of 
M48U1 and/or tenofovir alone or in combination in a 0.25% HEC vehicle gel using an organotypic model of 
Figure 3. The combined formulation of M48U1 and tenofovir in 0.25% HEC exhibited synergistic 
antiretroviral activity against infection with R5-tropic HIV-1BaL. Combinations of M48U1/tenofovir 
(0 μM/10 μM; 0.001 μM/5 μM; 0.005 μM/2.5 μM; 0.03 μM/1.25 μM; 0.15 μM/0.5 μM; 0.75 μM/0.1 μM and 
1.5 μM/0 μM were tested in PBMCs challenged with the HIV-1BaL strain and isobologram determination 
was performed (A). In particular, the M48U1/tenofovir combinations 0.005 μM/2.5 μM; 0.03 μM/1.25 μM; 
0.15 μM/0.5 μM were synergistic. Data for each compound are reported as the fractional inhibitory concentration 
(FIC), calculated by dividing the IC50 of compound “X” in combination with compound “Y” by the IC50 
of compound “X” alone. The solid and broken lines represent the unit lines for an FIC equal to 1 and 0.5, 
respectively. The FIC index, corresponding to the sum of the FIC values for compounds “X” and “Y,” is indicated 
for every combination of concentrations. An FIC index between 0.5 and 0.9 is suggestive of partial synergism, 
whereas an FIC index < 0.5 indicates significant synergism. In panel B, MacSynergy II analysis is shown. A 3D 
synergy plot, obtained at 95% confidence interval represents the synergism between M48U1 and tenofovir at 
different concentrations. Peaks above the theoretical additive plane (level 0) indicate synergy, whereas peaks 
below the plane indicate antagonism. Statistically significant synergies are shown using different colors, from red 
to pink, for each range of Synergy volume. Pink color indicates the strongest synergy. The synergy value volume 
was determined at 68.44 μM2% indicating the presence of synergy48. The data should be interpreted as follows: 
values between 25 and 50 μM2% minor but significant synergy, between 50 and 100 μM2% synergy, >100 μM2% 
strong synergy. These results were obtained from three independent experiments in triplicate.
Figure 4. The combination of M48U1 plus tenofovir was not toxic to PBMCs. Activated PBMCs were treated 
with the higher concentrations of M48U1 and/or tenofovir tested in the earlier studies. HIV-1 replication was 
monitored by Trypan blue technique on day 7 post-infection. The data were expressed as the means ± standard 
deviations (±SD) of viable cells relative to untreated controls (set to 100%) obtained from three independent 
experiments performed in triplicate.
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cervicovaginal epithelial tissue to determine the effectiveness of these formulations as a vaginal mucosal micro-
bicide. Different formulations of M48U1 (0.67 μM or 6.7 μM M48U1), tenofovir (2 μM or 20 μM) or the combi-
nation (0.67 μM M48U1 plus 2 μM tenofovir or 6.7 μM M48U1 plus 20 μM tenofovir) were applied in a 0.25% 
HEC hydrogel formulation to the apical surface of cervicovaginal cell cultures that were subsequently challenged 
with HIV-1BaL (25 ng HIV-1 p24/tissue) for 24 hours. We have tested these higher concentrations of M48U1 
(6.7 μM) and tenofovir (20 μM) because the cervicovaginal tissues and PBMCs have different susceptibilities to 
HIV-1 infection and treatment. Both HIV-1 and antiretroviral concentrations were increased according to several 
papers31,53,54. Moreover, this experimental analysis focused on the R5-tropic HIV-1 strain because the transmis-
sion of HIV-1 by sexual intercourse is almost exclusively determined by the CCR5 tropism10,39.
The presence of HIV-1 infection was evaluated with SYBR green-based quantitative real time PCR technique 
to determine the content of HIV-1 proviral DNA on day 4 post-infection using LTR-specific primers. The sam-
ples treated with 6.7 μM M48U1 or 20 μM tenofovir showed a decrease in the amount of proviral HIV-1 DNA by 
approximately 15-fold and 45-fold, respectively. This HIV-1 replication inhibition was detectable to a lesser extent 
when 0.67 μM M48U1 and 2 μM tenofovir concentrations were employed (7- and 11-fold, respectively). The com-
bination of M48U1 and tenofovir elicited a further decrease in HIV-1 DNA compared to either alone. In fact, 
when the combination of the higher concentrations was used (6.7 μM M48U1 plus 20 μM tenofovir), no HIV-1 
proviral DNA was detected by the quantitative PCR assay, and the combination of 0.67 μM M48U1 plus 2 μM 
tenofovir in 0.25% HEC induced a 29-fold decrease in the HIV-1 proviral DNA burden (Fig. 5).
Because the EpiVaginal cell model is a cellular system that is also suitable for predicting the vaginal toxicity of 
microbicides, we also assessed the irritation potential of M48U1 and/or tenofovir treatment. We treated the cervi-
covaginal tissues with 6.7 μM M48U1, 20 μM tenofovir, or the 6.7 μM M48U1 plus 20 μM tenofovir combination, 
all of which were formulated in 0.25% HEC hydrogel, for 1, 4, 18 and 96 hours at 37 °C. The samples were analysed 
for the cellular metabolic activity of living cells by the MTT kit and for the accumulation of dead cells by evalu-
ating the LDH release. In addition, we evaluated the release of IL-1α to determine the inflammatory cell activa-
tion. Table 1 showed that the M48U1 and/or tenofovir are not toxic at tested concentrations (p > 0.05; one-way 
ANOVA test) as well as LDH and IL-1α proinflammatory cytokine release was not significantly increased by the 
drug treatments (p > 0.05; two-way ANOVA test followed by Bonferroni test) with respect to untreated controls.
Discussion
This report investigated the antiretroviral activity of HEC-formulated tenofovir and M48U1 in both in vitro and 
ex vivo cellular models, including activated PBMCs, TZM-bl cells and a human organotypic model of cervico-
vaginal tissue. We observed that: (i) M48U1 and tenofovir suppressed infection of activated PBMCs with several 
HIV-1 reference strains and viral isolates from patients; (ii) M48U1 and tenofovir inhibited infection of TZM-bl 
cells with T/F IMCs; (iii) M48U1 and tenofovir exhibited synergistic antiretroviral effects; and (iv) M48U1 and/
or tenofovir treatments inhibited HIV-1 R5 strain replication in an ex vivo cervicovaginal tissue model without 
any significant effect on tissue viability.
M48U1 formulated in HEC effectively and reliably inhibited infection of PBMCs with laboratory HIV-1 
strains and with HIV-1 subtype B and C strains isolated from naïve and cART-treated patients. To develop a 
Figure 5. M48U1 plus tenofovir treatment of human cervicovaginal histocultures effectively prevented 
the replication of HIV-1BaL. Full thickness cervicovaginal histocultures were treated with two different 
concentrations of M48U1 (0.67 μM or 6.7 μM) with or without tenofovir at 2 μM or 20 μM formulated in 0.25% 
HEC hydrogel. In the presence of these drugs, the tissue samples were challenged with the HIV-1BaL strain 
(25 ng p24/well) for 24 hours. Total DNA was purified from the tissues on day 4 post-infection and was analysed 
by qPCR. When 6.7 μM M48U1 was used with 20 μM tenofovir, no proviral DNA was detectable. The data were 
expressed as the means ± standard deviations (±SD) of the number of copies of proviral DNA/200 ng total DNA 
and the fold-inhibition was calculated as the mean with respect to HIV-1-infected samples treated with HEC 
hydrogel (0.25%) without any antiretroviral drug. Three experiments in triplicate or duplicate were performed. 
ND: not detected.
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microbicide able to prevent HIV-1 transmission, it is essential to evaluate the activity of M48U1 on several pri-
mary virus strains, including transmitted/founder strains. Certain commonly used, laboratory strains are highly 
sensitive to inhibition of infection and thus do not adequately reflect the broad spectrum of inhibition observed 
for primary viruses of various clades. Suppressing the replication of HIV-1 subtype C viruses is highly relevant 
because these viruses account for approximately 50% of all infections worldwide and they are the most prevalent 
in sub-Saharan Africa55. In addition, M48U1 also inhibited T/F IMCs, which were derived from patients with 
acute infection and thus represent transmitted viruses acquired through a mucosal site in vivo. The broad antiret-
roviral activity of M48U1 and the synergistic activity of the M48U1 combined with tenofovir in the prevention 
of HIV infection could overcome the variability of HIV strains over time, as virus isolates from later stages of 
infection can differ substantially from the earlier virus population and in particular from the respective transmit-
ted virus strain(s). Overall, our findings demonstrated that the inhibition of HIV replication was not dependent 
on the subtype, HIV-1 tropism or stage of infection. Our analysis of the antiretroviral activity of tenofovir and 
M48U1 showed that tenofovir has lower antiviral effects on IMCs with respect to laboratory and wild type HIV-1 
strains. We have already shown that IMCs generally showed higher IC50 values in neutralization assays44 thus 
suggesting a possible higher resistance to some neutralizing compounds. Differences in neutralization sensitiv-
ity could also be due to technical manipulation of the different viral strains as IMCs have been produced in the 
context of a proviral background. Other studies have reported that different ratios of backbone and env-plasmids 
transfected in host cells were found to give rise to viral particles endowed with different envelope features, such 
as the proportion of env protein cleavage and the level of gp120 surface expression; such changes in envelope fea-
tures were found to affect viral infectivity, and, possibly, antibody reactivity56. In addition, the host cells are known 
to impact biochemical and structural features of virus particles, e.g. in terms of protein processing, folding and 
glycosylation patterns57. Indeed, in our study, diversity in the sensitivity to neutralization could be ascribed to the 
effect of the different host cells (293 T cells vs PBMC) as well.
M48U1 is a CD4 mimetic peptide (27 mer) that binds gp120 with higher affinity than that of the native CD4 
protein34,35. This property is due to the presence of a protrusion at amino acid 23 of M48U1, which stabilizes the 
Phe43 cavity, a critical element in the interaction between gp120 and CD458. The antiretroviral activity of M48U1 
was originally attributed to its inhibition of viral entry. However, another investigation indicated that this pep-
tide not only acts in the first phase of HIV-1 entry but also elicits gp120 shedding through binding to the gp120 
exposed on the cell membrane to induce the release of functionally defective HIV-1 particles59. This peptide 
represents a valuable new tool with respect to soluble CD4 (sCD4), which was only able to inhibit specific HIV-1 
strains and, under some experimental conditions, actually enhanced infection, especially with HIV-1 wild-type 
strains60–62. Intriguingly, M48U1 can suppress both cell-free and cell-to-cell HIV-1 infection61, suggesting that 
this drug may be a good candidate as a vaginal microbicide, especially because heterosexual transmission through 
the vaginal mucosa is mainly due to cell-free viruses but can also involve cell-to-cell HIV-1 transmission related 
to the transfer of HIV-1-infected lymphocytes and macrophages, detectable in the semen, to the cells present in 
the vaginal submucosa63,64. As M48U1 is stable in vaginal fluids and is very soluble at acidic pH30,36, its possible 
use as a single microbicide was proposed by a study in a simian model using an M48U1 vaginal gel, where M48U1 
prevented SHIV-1162P3 infection in Cynomolgus macaques30. In parallel, we analysed the effects of tenofovir for-
mulated in HEC on activated PBMCs and in TZM-bl cells. Tenofovir is an inhibitor of reverse transcriptase, 
which acts as a DNA chain terminator. Its modified form, tenofovir disoproxil fumarate, is currently used in 
cART regimens65,66. As expected54,67, tenofovir formulated in HEC maintained its antiretroviral activity in both 
cell models.
Viability (%) LDH release (Abs) IL-1α Release (pg/mL)
Untreated (1 hour) 100 + 5 0.211 ± 0.02 7.9 ± 0.9
20 μM tenofovir/0.25% HEC (1 hour) 95 + 4 0.207 ± 0.06 7.8 ± 0.8
6.7 μM M48U1/0.25% HEC (1 hour) 98 + 6 0.222 ± 0.05 8.0 ± 1.0
20 μM tenofovir + 6.7 μM M48U1/0.25% HEC (1 hour) 97 + 5 0.218 ± 0.05 8.4 ± 0.7
Untreated (4 hours) 100 + 4 0.368 ± 0.05 9.7 ± 1.3
20 μM tenofovir/0.25% HEC (4 hours) 96 + 6 0.381 ± 0.05 9.9 ± 1.8
6.7 μM M48U1/0.25% HEC (4 hours) 98 + 7 0.364 ± 0.01 10.5 ± 1.1
20 μM tenofovir + 6.7 μM M48U1/0.25% HEC (4 hours) 97 + 5 0.337 ± 0.01 10.3 ± 1.6
Untreated (18 hours) 100 + 8 1.179 ± 0.13 34.1 ± 2.6
20 μM tenofovir/0.25% HEC (18 hours) 88 + 4 0.922 ± 0.2 36.5 ± 1.2
6.7 μM M48U1/0.25% HEC (18 hours) 89 + 5 0.996 ± 0.2 33.8 ± 5.4
20 μM tenofovir + 6.7 μM M48U1/0.25% HEC (18 hours) 91 + 6 1.103 ± 0.1 34.6 ± 4.2
Untreated (96 hours) 100 + 6 1.557 ± 0.08 61.9 ± 5.8
20 μM tenofovir/0.25% HEC (96 hours) 104 + 9 1.498 ± 0.13 59.7 ± 7.7
6.7 μM M48U1/0.25% HEC (96 hours) 91 + 7 1.544 ± 0.15 62.2 ± 9.3
20 μM tenofovir + 6.7 μM M48U1/0.25% HEC (96 hours) 98 + 9 1.631 ± 0.21 64.0 ± 8.7
Table 1.  Evaluation of the viability (MTT assay), LDH release and IL-1α release in the EpiVaginal tissue 
model treated with M48U1 and/or tenofovir.
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We evaluated tenofovir as an antiretroviral drug for use with M48U1. Treatment with M48U1 plus tenofovir 
showed a clear synergism in the inhibition of HIV-1 replication in activated PBMCs, probably due to the different 
targets of these molecules in the HIV-1 replication cycle. Note that tenofovir has exhibited synergistic antiretro-
viral activity with many other antiretroviral molecules28,33,51,52, including all non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), some protease inhibitors (amprenavir, nelfinavir), the entry inhibitor Griffithsin and 
CADA. Combination treatment with two or more antiretroviral molecules is the current strategy for increasing 
the antiretroviral activity of microbicides. Interestingly, the advent of microbicide treatment has occurred in tan-
dem with the progressive improvement of systemic antiretroviral therapy, in which, the combinations of different 
antiretroviral drugs replaced the single antiretroviral compound treatment. In fact, microbicide treatment with a 
single drug has various weaknesses, including the failure of HIV-1 inhibition in the presence of specific resistant 
HIV-1 strains and the limited effectiveness of single treatment, which may not be potent enough to inhibit HIV-1 
transmission. In contrast, pharmacological approaches using multiple antiretroviral drugs have several advan-
tages, including the possibility of interfering with different phases of the viral replication cycle, the ability to use 
lower concentrations of individual drugs, which can decrease the risk of physical and functional damage to the 
vaginal epithelia, and the potential for interfering with the replication of drug-resistant strains.
In the last series of experiments in the present study, M48U1 plus tenofovir formulated in HEC effectively 
suppressed HIV-1 replication in ex vivo human cervicovaginal histocultures. Quantitative analysis of the proviral 
DNA indicated that the combination of 0.67 μM M48U1 plus 2 μM tenofovir exhibited a high level of inhibition 
of HIV-1 replication, which was relatively similar to the effects of single drug treatment at a 10-fold higher con-
centration. In addition, our results indicate that the combination of M48U1 and tenofovir was not toxic to the 
human cervicovaginal histocultures. This finding is in line with the absence of M48U1 toxicity and the stability 
of the peptide at vaginal pH in a simian model30 as well as with the extensive studies on tenofovir both in vivo 
and ex vivo, which showed that this drug has consistent tolerability and safety in different gel formulations26,54. 
Tenofovir was the first reverse transcriptase inhibitor to be successfully used as a microbicide in topical gel for-
mulations in human trials24, and an analysis of tenofovir treatment using a vaginal gel demonstrated the presence 
of tenofovir at high concentrations in vaginal tissues and in cellular models68,69. Importantly, tenofovir can impair 
HIV-1 transmission through an additional mechanism inhibiting HSV-2 infection24,68,70. In the CAPRISA 004 
trial, HSV-2 infections decreased by 51% in patients treated with tenofovir24,68,70. This anti-HSV-2 effect is impor-
tant to counteract the spread of HIV-1, because HSV-2 infection induces genital epithelial ulcers that increase 
the risk of HIV-1 transmission due to the disruption of mucosal barriers and induction of inflammation64,71. 
Epidemiological observations demonstrated that the risk for HIV-1 infection transmission was twice as high for 
women infected with HSV-272. In the present study, M48U1 and/or tenofovir were combined in HEC hydrogel, 
which is considered to be a universal vehicle gel, with no toxicity evident in cell cultures54,67. Our data confirmed 
the absence of cell damage or cell death induced by 0.25% HEC in both PBMCs and in organotypic cervicovagi-
nal tissues. In addition, as expected54, the 0.25% HEC formulation did not inhibit the diffusion of tenofovir and 
M48U1 to allow them to interact with cells and HIV-1. The combined use of tenofovir and M48U1 is valuable as 
a potential new microbicide treatment, with several advantages including drug synergism, the absence of toxicity 
and the possibility to interfere in two different stages of HIV-1 replication. In particular, the level of synergy could 
allow for the use of a lower amount of each drug to give an optimal antiretroviral effect with a possible reduction 
of drug side effects. In conclusion, these results suggest that M48U1 plus tenofovir treatment may be considered 
as a useful topical microbicide to counteract heterosexual transmission of HIV-1.
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